You are here

FDA Approves New Version of Transcatheter Heart Valve Device

Recapturable and repositionable valve improves positioning accuracy

The FDA has give the green light to the CoreValve Evolut R system (Medtronic) for transcatheter aortic valve replacement (TAVR) in patients with severe aortic stenosis who are at high or extreme risk for surgery.

The new system consists of the CoreValve Evolut R transcatheter valve and the EnVeoR delivery system, which features an InLine sheath that reduces the profile to less than 1/5 inch. A smaller profile size provides a greater opportunity to treat an expanded patient population with smaller vessels (down to 5.0 mm) through the preferred transfemoral access route, which may minimize the risk of major vascular complications in some patients, according to the manufacturer. An extended sealing skirt on the 26-mm and 29-mm valve sizes is intended to further promote valve sealing at the annulus.

In March, initial clinical outcomes for the CoreValve Evolut R system were presented at the 64th annual scientific session of the American College of Cardiology. At 30 days, all recapture attempts were performed safely with no strokes. In addition, correct valve position with one device was achieved in 98.3% of patients, and there were no cases of valve dysfunction, procedural death, annular rupture, coronary occlusion, valve embolization, or conversion to surgery. The pacemaker rate was low at 11.7%.

The approval of the Evolut R system makes it the first self-expanding, recapturable transcatheter heart valve available in the U.S. It comes in 23-mm, 26-mm, and 29-mm sizes.

Sources: Medtronic; June 23, 2015; and Medtronic; March 14, 2015.


Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug